MEA CRISPR Gene Detection and Diagnostics Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-31
- Report ID: 144010
- Pages: 225
-
Format:
Short Description
Middle East and Africa CRISPR Gene Detection and Diagnostic Market, By Class (Class 1- Multiple Effector Proteins and Class 2 -Single CrRNA-Binding Protein), Products & Services (Products and Services), Application (Biomedical Diagnostics, Genome Engineering, Drug Discovery, Agricultural Applications and Others), Workflow (Sample Preparation, Pre-Amplification, CrRNA, Cas Enzymes and Sensing), End User (Hospitals, Diagnostic Centers, Biotechnology Companies, Academic and Research Institutes and Others), Distribution Channel (Direct Tender, Retail Sales) Country (South Africa, Egypt, Israel, UAE, Saudi Arabia, Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Market Definition:
CRISPR is clustered regularly interspaced short palindromic repeats, is a tool for genome editing, meaning it allows researchers to easily alter DNA sequences and modify gene function. It has many potential applications, including correcting genetic defects, treating and preventing the spread of diseases. CRISPR-based diagnostics have been used for a wide range of biomedical applications, such as the sensing of nucleic-acid-based biomarkers of infectious and non-infectious diseases and for detection of genetic diseases. The assay kits in CRISPR is made up of two components: a protein called Cas9 and a guide RNA, a string of nucleic acid molecules with a certain genetic code.
This CRISPR-Cas9 system has been modified for use in mammalian cells. By introducing a guide sequence (sgRNA) specific for our gene of interest, we can either knock-out specific genes through introducing frame shift mutations via Non-Homologous End Joining (NHEJ), or generate knock-in mutations.
CRISPR-Cas 9 system have extended the scope of diagnostics and services for use in gene and cell therapies. Pharmaceutical companies are investing heavily in R&D to develop new products, with a surge of gene and cell therapy agents now entering early development. The market players are investing would allow to achieve the goal of producing safe and effective treatments for patients who are in serious need.
Market Segmentation:
The Middle East and Africa CRISPR gene detection and diagnostic market is categorized into six segments: class, products and services, application, workflow, end user, and distribution channel.
On the basis of class, the Middle East and Africa CRISPR gene detection and diagnostic market is segmented into class 1- multiple effector proteins and class 2 -single crRNA-binding protein.
On the basis of products and services, the Middle East and Africa CRISPR gene detection and diagnostic market is segmented into products and services.
On the basis of application, the Middle East and Africa CRISPR gene detection and diagnostic market is segmented into biomedical diagnostics, genome engineering, drug discovery, agricultural applications and others.
On the basis of workflow, the Middle East and Africa CRISPR gene detection and diagnostic market is segmented into sample preparation, pre-amplification, crRNA, Cas enzymes and sensing.
On the basis of end user, the Middle East and Africa CRISPR gene detection and diagnostic market is segmented into hospitals, diagnostic centers, biotechnology companies, academic and research institutes and others.
On the basis of distribution channel, the Middle East and Africa CRISPR gene detection and diagnostic market is segmented into direct tenders, retail sales.
Market Players
Some of the major players operating in the market are:
GenScript
Takara Bio Inc.
Agilent Technologies, Inc.
Merck KGaA
Integrated DNA Technologies, Inc. (A subsidiary of Danaher)
Thermo Fisher Scientific Inc.
TABLE OF CONTENTS
1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 OVERVIEW OF MIDDLE EAST & AFRICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET 21
1.4 CURRENCY AND PRICING 23
1.5 LIMITATIONS 23
1.6 MARKETS COVERED 24
2 MIDDLE EAST & AFRICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: SEGMENTATION 27
2.1 MARKETS COVERED 27
2.2 GEOGRAPHICAL SCOPE 28
2.3 YEARS CONSIDERED FOR THE STUDY 29
2.4 DBMR TRIPOD DATA VALIDATION MODEL 30
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 33
2.6 MULTIVARIATE MODELLING 34
2.7 CLASS SEGMENT LIFELINE CURVE 34
2.8 DBMR MARKET POSITION GRID 35
2.9 VENDOR SHARE ANALYSIS 37
2.10 MARKET END USER COVERAGE GRID 38
2.11 SECONDARY SOURCES 39
3 EXECUTIVE SUMMARY 40
4 PREMIUM INSIGHTS 44
4.1 PESTEL 45
4.2 PORTER'S FIVE FORCES MODEL 46
5 INTELLECTUAL PROPERTY LANDSCAPE (PATENT LANDSCAPE) 47
6 EPIDEMIOLOGY 50
7 MIDDLE EAST & AFRICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: REGULATORY SCENARIO 51
8 PIPELINE ANALYSIS FOR MIDDLE EAST & AFRICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, OF CRISPR DIAGNOSTICS 53
9 MARKET OVERVIEW 54
9.1 DRIVERS 56
9.1.1 RISE IN PREVALENCE AND INCIDENCE OF CHRONIC DISEASES 56
9.1.2 RISE IN INVESTMENT IN RESEARCH AND DEVELOPMENT 58
9.1.3 AVAILABILITY OF FUNDING FOR CRISPR GENE DIAGNOSTICS 59
9.1.4 RISE IN GMP-CERTIFICATION APPROVALS FOR CRISPR GENE DIAGNOSTIC 59
9.1.5 RISE IN CLINICAL TRIALS FOR CRISPR BASED DIAGNOSTICS 59
9.2 RESTRAINTS 60
9.2.1 RISE IN COST OF CRISPR BASED DIAGNOSTICS 60
9.2.2 RISKS FACED WHILE USING CRISPR DIAGNOSIS 60
9.2.3 ETHICAL CONCERNS RELATED TO CRISPR GENE DETECTION AND DIAGNOSTIC RESEARCH 61
9.2.4 AVAILABILITY OF ALTERNATIVES 61
9.3 OPPORTUNITIES 61
9.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS 61
9.3.2 RISE IN HEALTHCARE EXPENDITURE 62
9.3.3 EMERGENCE OF TECHNOLOGICAL ADVANCEMENTS IN CRISPR BASED DIAGNOSTICS 62
9.4 CHALLENGES 63
9.4.1 LACK OF SKILLED PROFESSIONALS REQUIRED FOR CRISPR DIAGNOSTICS 63
9.4.2 STRINGENT REGULATIONS 63
10 MIDDLE EAST & AFRICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS 65
10.1 OVERVIEW 66
10.2 CLASS-2 SINGLE CRRNA-BINDING PROTEIN 69
10.2.1 BIOMEDICAL DIAGNOSTICS 70
10.2.2 AGRICULTURAL APPLICATIONS 70
10.2.3 GENOME ENGINEERING 70
10.2.4 DRUG DISCOVERY 70
10.2.5 OTHERS 70
10.3 CLASS-1 MULTIPLE EFFECTOR PROTEINS 71
11 MIDDLE EAST & AFRICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES 72
11.1 OVERVIEW 73
11.2 PRODUCTS 76
11.2.1 ASSAY KITS 77
11.2.1.1 SGRNA KIT 77
11.2.1.2 GENOMIC DETECTION KIT 77
11.2.1.3 OTHERS 78
11.2.2 PROTEINS 78
11.2.2.1 CAS9 78
11.2.2.2 CPF1 78
11.2.2.3 OTHERS 78
11.2.3 PLASMID AND VECTOR 79
11.2.4 LIBRARY 79
11.2.5 CONTROL KITS 79
11.2.6 DELIVERY SYSTEM PRODUCTS 79
11.2.7 DESIGN TOOLS 79
11.2.8 GENOMIC RNA 79
11.2.9 HDR BLOCKERS 79
11.2.9.1 AZIDOTHYMIDINE 80
11.2.9.2 TRIFLUOROTHYMIDINE 80
11.2.9.3 OTHERS 80
11.2.9.4 OTHERS 80
11.3 SERVICES 80
11.3.1 G-RNA DESIGN 81
11.3.2 CELL LINE ENGINEERING 81
11.3.3 MICROBIAL GENE EDITING 81
11.3.4 DNA SYNTHESIS 82
11.3.5 OTHERS 82
12 MIDDLE EAST & AFRICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION 83
12.1 OVERVIEW 84
12.2 BIOMEDICAL DIAGNOSTICS 87
12.2.1 CANCER 88
12.2.2 BLOOD DISORDERS 88
12.2.3 HEREDITARY DISORDERS 88
12.2.4 MUSCULAR DYSTROPHY 88
12.2.5 AIDS 88
12.2.6 NEURODEGENERATIVE CONDITION 88
12.2.7 OTHERS 89
12.3 AGRICULTURAL APPLICATIONS 89
12.4 GENOME ENGINEERING 89
12.4.1 CELL LINE ENGINEERING 90
12.4.2 HUMAN STEM CELLS 90
12.5 DRUG DISCOVERY 91
12.6 OTHERS 92
13 MIDDLE EAST & AFRICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW 93
13.1 OVERVIEW 94
13.2 CRRNA 97
13.3 CAS ENZYME 97
13.4 PRE-AMPLIFICATION 98
13.4.1 PCR 99
13.4.2 LAMP 99
13.4.3 RPA 99
13.5 SAMPLE PREPARATION 99
13.6 SENSING 100
13.6.1 FLUORESCENT PROBES 101
13.6.2 COLORIMETRIC 101
14 MIDDLE EAST & AFRICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER 102
14.1 OVERVIEW 103
14.2 BIOTECHNOLOGY COMPANIES 106
14.3 ACADEMIC AND RESEARCH INSTITUTES 107
14.4 DIAGNOSTIC CENTERS 108
14.5 HOSPITALS 109
14.6 OTHERS 110
15 MIDDLE EAST & AFRICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL 111
15.1 OVERVIEW 112
15.2 DIRECT TENDER 116
15.3 RETAIL SALES 117
16 MIDDLE EAST & AFRICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION 118
16.1 MIDDLE EAST AND AFRICA 119
16.1.1 ISRAEL 128
16.1.2 SOUTH AFRICA 133
16.1.3 U.A.E 138
16.1.4 EGYPT 143
16.1.5 SAUDI ARABIA 148
16.1.6 REST OF MIDDLE EAST AND AFRICA 153
17 MIDDLE EAST & AFRICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: COMPANY LANDSCAPE 154
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 154
18 SWOT ANALYSIS 155
19 COMPANY PROFILE 156
19.1 THERMO FISHER SCIENTIFIC INC. 156
19.1.1 COMPANY SNAPSHOT 156
19.1.2 REVENUE ANALYSIS 156
19.1.3 COMPANY SHARE ANALYSIS 157
19.1.4 PRODUCT PORTFOLIO 157
19.1.5 RECENT DEVELOPMENTS 158
19.2 MERCK KGA 159
19.2.1 COMPANY SNAPSHOT 159
19.2.2 REVENUE ANALYSIS 159
19.2.3 COMPANY SHARE ANALYSIS 160
19.2.4 PRODUCT PORTFOLIO 160
19.2.5 RECENT DEVELOPMENTS 161
19.3 AGILENT TECHNILOGIES, INC 163
19.3.1 COMPANY SNAPSHOT 163
19.3.2 REVENUE ANALYSIS 163
19.3.3 COMPANY SHARE ANALYSIS 164
19.3.4 PRODUCT PORTFOLIO 164
19.3.5 RECENT DEVELOPMENT 165
19.4 INTEGRATED DNA TECHNOLOGIES, INC. (A SUBSIDIARY OF DANAHER) 166
19.4.1 COMPANY SNAPSHOT 166
19.4.2 REVENUE ANALYSIS 166
19.4.3 COMPANY SHARE ANALYSIS 167
19.4.4 PRODUCT PORTFOLIO 167
19.4.5 RECENT DEVELOPMENTS 168
19.5 GENSCRIPT 169
19.5.1 COMPANY SNAPSHOT 169
19.5.2 REVENUE ANALYSIS 169
19.5.3 COMPANY SHARE ANALYSIS 170
19.5.4 PRODUCT PORTFOLIO 170
19.5.5 RECENT DEVELOPMENT 171
19.6 10 X GENOMICS 172
19.6.1 COMPANY SNAPSHOT 172
19.6.2 REVENUE ANALYSIS 172
19.6.3 PRODUCT PORTFOLIO 173
19.6.4 RECENT DEVELOPMENTS 173
19.7 APPLIED STEM CELL 174
19.7.1 COMPANY SNAPSHOT 174
19.7.2 PRODUCT PORTFOLIO 174
19.7.3 RECENT DEVELOPMENT 174
19.8 ADDGENE 175
19.8.1 COMPANY SNAPSHOT 175
19.8.2 PRODUCT PORTFOLIO 175
19.8.3 RECENT DEVELOPMENT 175
19.9 BIOVISION INC. 176
19.9.1 COMPANY SNAPSHOT 176
19.9.2 PRODUCT PORTFOLIO 176
19.9.3 RECENT DEVELOPMENT 177
19.10 CELLECTA, INC 178
19.10.1 COMPANY SNAPSHOT 178
19.10.2 PRODUCT PORTFOLIO 178
19.10.3 RECENT DEVELOPMENTS 179
19.11 CAS TAG BIOSCIENCES 180
19.11.1 COMPANY SNAPSHOT 180
19.11.2 PRODUCT PORTFOLIO 180
19.11.3 RECENT DEVELOPMENT 180
19.12 GENECOPOEIA, INC. 181
19.12.1 COMPANY SNAPSHOT 181
19.12.2 PRODUCT PORTFOLIO 181
19.12.3 RECENT DEVELOPMENT 181
19.13 HORIZON DISCOVERY LTD 182
19.13.1 COMPANY SNAPSHOT 182
19.13.2 PRODUCT PORTFOLIO 182
19.13.3 RECENT DEVELOPMENTS 183
19.14 HERA BIOLABS 184
19.14.1 COMPANY SNAPSHOT 184
19.14.2 PRODUCT PORTFOLIO 184
19.14.3 RECENT DEVELOPMENT 185
19.15 NEW ENGLAND BIOLABS 186
19.15.1 COMPANY SNAPSHOT 186
19.15.2 PRODUCT PORTFOLIO 186
19.15.3 RECENT DEVELOPMENTS 187
19.16 ORIGENE TECHNOLOGIES, INC. 188
19.16.1 COMPANY SNAPSHOT 188
19.16.2 PRODUCT PORTFOLIO 188
19.16.3 RECENT DEVELOPMENT 189
19.17 SYNTHEGO 190
19.17.1 COMPANY SNAPSHOT 190
19.17.2 PRODUCT PORTFOLIO 190
19.17.3 RECENT DEVELOPMENTS 190
19.18 TAKARA BIO INC. 192
19.18.1 COMPANY SNAPSHOT 192
19.18.2 REVENUE ANALYSIS 192
19.18.3 PRODUCT PORTFOLIO 193
19.18.4 RECENT DEVELOPMENT 193
19.19 TOOLGEN, INC. 194
19.19.1 COMPANY SNAPSHOT 194
19.19.2 PRODUCT PORTFOLIO 194
19.19.3 RECENT DEVELOPMENT 194
20 QUESTIONNAIRE 195
21 RELATED REPORTS 198
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
